We read with interest the D-CARE trial report by Robert Coleman and colleagues1 on the adjuvant administration of denosumab in patients with early-stage breast cancer. Despite the negative results, which pose concerns about high dose denosumab schedules in an adjuvant setting, this large and well- designed trial can provide useful clinical data that are usually difficult to obtain from observational studies, particularly regarding medication- related osteonecrosis of the jaw (MRONJ).

Fusco V., Campisi G., Bedogni A. (2020). Adjuvant denosumab in early breast-cancer. THE LANCET ONCOLOGY, 21(3), e124 [10.1016/S1470-2045(20)30066-8].

Adjuvant denosumab in early breast-cancer

Fusco V.;Campisi G.;Bedogni A.
2020-01-01

Abstract

We read with interest the D-CARE trial report by Robert Coleman and colleagues1 on the adjuvant administration of denosumab in patients with early-stage breast cancer. Despite the negative results, which pose concerns about high dose denosumab schedules in an adjuvant setting, this large and well- designed trial can provide useful clinical data that are usually difficult to obtain from observational studies, particularly regarding medication- related osteonecrosis of the jaw (MRONJ).
Fusco V., Campisi G., Bedogni A. (2020). Adjuvant denosumab in early breast-cancer. THE LANCET ONCOLOGY, 21(3), e124 [10.1016/S1470-2045(20)30066-8].
File in questo prodotto:
File Dimensione Formato  
PIIS1470204520300668.pdf

Solo gestori archvio

Tipologia: Versione Editoriale
Dimensione 32.97 kB
Formato Adobe PDF
32.97 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/408720
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact